Benzinga
Benzinga
Benzinga
lunes, septiembre 21

Coya Therapeutics Inc

COYANASDAQ
Trade with Public
Trade with Public
$4.89
0.132.73%
al cierre: Sep 18, 5:00 PM EST
$4.89
N/A
After hour: Sep 18, 4:02 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Coya Therapeutics Financials

Coya Therapeutics (COYA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Coya Therapeutics Q2 EPS $(0.28) Beats $(0.34) Estimate, Sales $243.745K Beat $100.000K Estimate

Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.34) by 17.65 percent. This is a 22.22 percent increase over losses of $(0.36) per share
Benzinga Newsdesk

PRO
Coya Therapeutics Q1 EPS $(0.32) Beats $(0.41) Estimate, Sales $251.147K Beat $125.000K Estimate

Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.41) by 21.95 percent. This is a 27.27 percent increase over losses of $(0.44) per share from
Benzinga Newsdesk

PRO
Coya Therapeutics Q4 EPS $(0.34) Misses $(0.28) Estimate, Sales $3.960M Beat $1.928M Estimate

Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.28) by 21.86 percent. This is a 88.89 percent decrease over losses of $(0.18) per share
Benzinga Newsdesk

PRO
Coya Therapeutics Q3 EPS $(0.13) Beats $(0.28) Estimate, Sales $3.564M Miss $3.700M Estimate

Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.28) by 53.57 percent. This is a 50 percent increase over losses of $(0.26) per share from
Benzinga Newsdesk

PRO
Coya Therapeutics Q2 EPS $(0.36) Beats $(0.42) Estimate, Sales $163.616K Miss $940.000K Estimate

Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.42) by 13.46 percent. This is a 89.47 percent decrease over losses of $(0.19) per share from
Benzinga Newsdesk

PRO
Coya Therapeutics Q1 EPS $(0.44) Misses $(0.20) Estimate, Sales $257.88K Miss $2.63M Estimate

Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.20) by 120 percent. This is a 25.71 percent decrease over losses of $(0.35) per share from
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved